PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China

OBJECTIVE: Our previous economic assessment found that nivolumab was not cost-effective for Chinese patients with advanced non-small cell lung cancer (NSCLC) and without EGFR mutations or ALK translocations, when compared with the standard second-line drug docetaxel. However, a greater survival bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiao, Luo, Xia, Zhou, Zhen, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Tan, Chongqing, Zeng, Xiaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710478/
https://www.ncbi.nlm.nih.gov/pubmed/34966668
http://dx.doi.org/10.3389/fonc.2021.745493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710478/
https://www.ncbi.nlm.nih.gov/pubmed/34966668
http://dx.doi.org/10.3389/fonc.2021.745493

Ejemplares similares